Table 4 Outcomes of included studies
Outcome | Lárraga et al. [30] | Didden et al. [29] | Persson et al. [28] | Verschuur et al. [27] | Homs et al. [26] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
FCSEMS N = 21 | PCSEMS N = 29 | FCSEMS N = 48 | PCSEMS N = 49 | FCSEMS N = 48 | PCSEMS N = 47 | FCSEMS N = 42 | PCSEMS N = 42 | FCSEMS N = 70 | PCSEMS (Ultraflex) N = 75 | PCSEMS (Flamingo) N = 71 | |
Technical success | 21 (100%) | 29 (100%) | 48 (100%) | 47 (95.91%) | 45 (93.75%) | 43 (91.48%) | 40 (95.23%) | 42 (100%) | NR | NR | NR |
Stent Migration | 4 (19.04%) | 5 (17.24%) | 4 (8.33%) | 3 (6.12%) | 9 (18.75%) | 14 (29.78%) | 5 (11.9%) | 7 (16.66%) | 4 (5.71%) | 17 (22.66%) | 5 (7.04%) |
Stent obstruction by tumor | 0 | 5 (17.24%) | 5 (10.41%) | 7 (14.28%) | 0 | 2 (4.25%) | 10 (23.81%) | 13 (30.95%) | 11 (15.71%) | 7 (9.33%) | 12 (16.9%) |
Stent obstruction by food | 2 (9.52%) | 2 (6.9%) | 0 | 1 (2%) | 0 | 5 (10.63%) | 1 (2.38%) | 0 | 1 (1.42%) | 10 (13.33%) | 5 (7.04%) |
Chest Pain | 1 (4.76%) | 2 (6.9%) | 9 (18.75%) | 9 (18.36%) | NR | NR | 2 (4.76%) | 1 (2.38%) | NR | NR | NR |
Bleeding | 0 | 1 (3.45%) | 4 (8.33%) | 5 (10.2%) | NR | NR | 2 (4.76%) | 5 (11.9%) | NR | NR | NR |